NCI Proposes Inviting Academic Labs To Submit New Therapies For Development
In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm
Research Funding: 30 Groups Sign Letter For Double NCI Budget
Tobacco Regulation: ACS Advocates Giving FDA Full Authority Over Tobacco
Funding Opportunities: March 1 Deadline For ACS Fellowships; Program Announcements
NIH On R29 Phase-Out; Grant Review Appeals Process Changed
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
